Summary
This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination
with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part
1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion
cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion
Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in
TROP2-ADC-naive patients).